Precision BioSciences reported diluted earnings per share of $1.05 for the quarter ended December 31, 2025, a $1.59 per‑share beat over the consensus estimate of a $0.54 loss. The company’s revenue rose to $34.2 million, far exceeding the $9.075 million forecasted by analysts, a $25.1 million upside that reflects a one‑time $26.2 million recognition from the conclusion of its Novartis collaboration and an $8.0 million milestone payment from the Imugene license agreement.
The Q4 revenue surge is a stark contrast to the $0.6 million generated in the same quarter of 2024, and it comes at a time when the company’s full‑year revenue fell to $34.3 million from $68.7 million in 2024. The decline in annual revenue is largely attributable to the wind‑down of prior collaborations, which had previously driven higher top lines. Despite the revenue dip, the company posted a net income of $20.1 million for the quarter, compared with a $17.8 million loss in Q4 2024, underscoring the impact of the one‑time collaboration revenue and disciplined cost management.
Management highlighted the significance of the results, stating, "2025 was an exceptional year for Precision BioSciences marked by meaningful clinical and financial progress. We delivered on what we committed to achieve and more in 2025." CEO Michael Amoroso added, "We continue to make steady, disciplined progress across our clinical‑stage programs. With multiple dosing cohorts underway in our global Phase 1/2a ELIMINATE‑B trial, our first‑in‑class gene editing approach for DMD entering the clinic in early 2026, and cash runway through 2028, we expect continued operational excellence this year with clear clinical and regulatory milestones for these potentially transformative therapies."
The earnings beat is driven primarily by the one‑time revenue recognition from the Novartis collaboration wind‑down and the Imugene milestone, rather than organic growth. While the Q4 results signal a strong rebound, the company’s full‑year outlook remains cautious, with a net loss of $45.7 million for 2025 versus a $7.2 million profit in 2024. The extended cash runway through 2028, supported by a $75 million equity offering that raised the company’s cash balance to $137.2 million, provides a buffer for continued investment in its pipeline, including the PBGENE‑HBV and PBGENE‑DMD programs.
Overall, the Q4 earnings demonstrate Precision BioSciences’ ability to convert collaboration milestones into profitable quarters, while the broader revenue decline highlights the need for sustained organic growth to offset the loss of collaboration income. The company’s focus on advancing its clinical pipeline and maintaining a robust cash position positions it to navigate the upcoming regulatory milestones and potential market expansion in the gene‑editing space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.